Novo Nordisk briefly overtakes LVMH as Europe's most valuable company

Danish drugmaker Novo Nordisk briefly surpassed LVMH as Europe's most valuable listed company, driven by high demand for its diabetes and weight-loss drugs, while LVMH has been affected by concerns over the Chinese economy.

reuters.com

Relevant topic timeline:

8/21/2023

How soaring demand for Ozempic and Wegovy is altering Denmark's economy

Sales of the weight-loss drug Wegovy, manufactured by Novo Nordisk, have led to lower interest rates in Denmark due to an influx of US dollars into the country's economy, which has pushed up the value of the Danish krone.

8/25/2023

Weight-Loss Drug Wegovy Will Launch In More Countries Despite Ongoing Struggles Over Stellar Demand, CEO Says

Novo Nordisk plans to launch its weight-loss drug Wegovy in more countries, despite shortages caused by high demand, according to CEO Lars Fruergaard Jorgensen.

9/4/2023

Weight-loss drug Wegovy debuts in UK even as Novo Nordisk struggles with supplies

Novo Nordisk has launched its weight-loss injection, Wegovy, in the UK, following a controlled and limited launch, with a monthly supply priced between £199 and £299 for private patients through an online pharmacy chain.

9/6/2023

Denmark's economy boosted by anti-obesity treatments

The Danish pharmaceutical company Novo Nordisk is driving the country's economic growth, with its profits and production of anti-obesity drugs contributing significantly to the GDP and employment rates.

9/13/2023

Novo Nordisk Shares Drop After Stock Split, But Long Term Growth Prospects Still Strong Despite Valuation Concerns

Danish drugmaker Novo Nordisk's shares fell after a split aimed at increasing liquidity, but analysts remain optimistic about the company's leadership in the obesity drug market.

9/20/2023

New Obesity Drugs Could Transform Health but Disrupt Major Industries

Anti-obesity drugs developed by Novo Nordisk and Eli Lilly have the potential to transform public health but could also disrupt industries such as food, fitness, and healthcare, affecting companies like Nestlé and McDonald's.